{
    "root": "3f053e7a-0f0f-4e33-8288-15aaf51f6c56",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "REZLIDHIA",
    "value": "20250430",
    "ingredients": [
        {
            "name": "OLUTASIDENIB",
            "code": "0T4IMT8S5Z",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16267"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": {
        "text": "relapsed refractory acute myeloid leukemia rezlidhia indicated treatment adult patients relapsed refractory acute myeloid leukemia ( aml ) susceptible isocitrate dehydrogenase-1 ( idh1 ) mutation detected fda-approved test [ ( 2.1 ) , pharmacology ( 12.1 ) , ( 14.1 ) ] .",
        "doid_entities": [
            {
                "text": "acute myeloid leukemia (DOID:9119)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9119"
            },
            {
                "text": "myeloid leukemia (DOID:8692)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8692"
            },
            {
                "text": "leukemia (DOID:1240)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1240"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute myeloid leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_519"
            }
        ]
    },
    "contraindications": {
        "text": "select patients based presence idh1 mutation ( ) . ( 2.1 ) recommended : 150 mg orally twice daily , disease progression unacceptable toxicity . ( 2.2 ) take empty stomach least 1 hour 2 hours meal . ( 2.2 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied capsule strength description package configuration ndc number 150 mg white hard gelatin capsules black ink print `` olu 150 `` white high-density polyethylene ( hdpe ) bottle child-resistant closure 71332-005-01 bottle contains 30 capsules storage store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "none .",
    "indications_original": "Relapsed or Refractory Acute Myeloid Leukemia\n                  \n                  REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration (2.1), Clinical Pharmacology (12.1), and Clinical Studies (14.1)].",
    "contraindications_original": "Select patients based on presence of IDH1 mutation(s). ( 2.1 ) Recommended dosage: 150 mg orally twice daily, until disease\nprogression or unacceptable toxicity. ( 2.2 ) Take on an empty stomach at least 1 hour before or 2 hours after a\nmeal. ( 2.2 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           Capsule Strength\n                           Description\n                           Package Configuration\n                           NDC Number\n                        \n                        \n                           150 mg\n                           White hard gelatin capsules with black ink print \"OLU 150\"\n                           White high-density polyethylene (HDPE) bottle with child-resistant closure\n                           71332-005-01\n                        \n                        \n                           \n                           \n                           Each bottle contains 30 capsules\n                           \n                        \n                     \n                  \n                  \n                     Storage\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F)[see USP Controlled Room Temperature].",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "REZLIDHIA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16267"
        }
    ]
}